First 10-year follow-up shows that treatment with AVONEX leads to long-term benefits in early multiple sclerosis patients

Thursday, April 30, 2009 - 09:49 in Health & Medicine

SEATTLE, WA - April 30, 2009 - Biogen Idec (NASDAQ: BIIB) today announced data results from the CHAMPIONS (Controlled High-Risk AVONEX(R) (interferon beta-1a) Multiple Sclerosis (MS) Prevention Study In Ongoing Neurologic Surveillance) study, an open label follow-up to CHAMPS (Controlled High Risk Subjects AVONEX MS Prevention Study).

Read the whole article on Science Blog

More from Science Blog

Latest Science Newsletter

Get the latest and most popular science news articles of the week in your Inbox! It's free!

Check out our next project, Biology.Net